AC Immune SA, a leader in drug development for Alzheimer's disease, has announced that the World Economic Forum has elected as AC Immune Technology Pioneer 2009 for his achievements as a leader in innovation and their revolutionary technologies that can have a profound impact on business and society.
In addition, AC Immune reported to have reached significant milestones in the clinical development of innovative therapies against Alzheimer enfermedaddel. Regulatory authorities have approved the application for phase II clinical trial of ICA-91 small-molecule to treat Alzheimer's disease mild to moderate.
Thirdly, we found that AC Immune Genentech Inc., which develops anti-Abeta antibody into an exclusive licensing agreement with AC Immune, received quick approval of the designation by the Food and Drug Administration U.S. (FDA) for clinical development program in Alzheimer's disease mild to moderate. The recruitment of the first patient in Phase I clinical trial during the third quarter of 2008 triggered a milestone payment to AC Immune of an undisclosed amount.